Inhibikase Therapeutics Shares Rise Following $100M Offering and Phase 3 Study Announcement

Inhibikase Therapeutics shares are trading higher after the company announced the pricing of a $100 million public offering and plans to advance IKT-001 to a global pivotal Phase 3 study for PAH.